X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

APGNW

Closed

Apexigen Inc.

0.026
0.000 (0.00%)
Last Update: 23 Aug 2023 16:30:00
Yesterday: 0.0261
Day's Range: 0.026 - 0.026
Send
When Written:
 
0.0601
Apexigen Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel antibody-based therapeutics for the treatment of cancer and other diseases. The company was founded in 2006 and is headquartered in San Carlos, California.

Apexigen's proprietary platform technology, APXiMAB™, enables the discovery and development of high-quality antibodies with enhanced therapeutic properties, including increased potency, specificity, and stability. The company's pipeline includes a range of antibody-based drugs for the treatment of various cancers, including lung, breast, ovarian, and pancreatic cancers.

Apexigen has collaborations with several leading pharmaceutical companies, including Bristol Myers Squibb, Janssen Biotech, and BioNTech, to develop and commercialize its antibody-based therapeutics. The company has also received several grants and awards from organizations such as the National Cancer Institute and the California Institute for Regenerative Medicine to support its research and development efforts.

Overall, Apexigen is a leading biopharmaceutical company that is focused on developing innovative antibody-based therapeutics to address unmet medical needs in cancer and other diseases.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X